Compare Vaxcyte Inc. Common Stock (PCVX) vs Southern Company (SO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Southern Company — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Southern Company trades at $89.4 (market cap $101.36B). The key difference: Southern Company is far larger — about 9.6× Vaxcyte Inc. Common Stock's market cap, and Southern Company pays a 3.45% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Southern Company for 17 Days on average.
| PCVX | SO | |
|---|---|---|
Market Cap | $10.51B | $101.36B |
Volume | 2,644,694 | 6,566,089 |
Sector | Health | Utilities |
52-Week High | $73.82 | $99.72 |
52-Week Low | $40.32 | $82.35 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $9.14B | $175.46B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Southern Company (SO) trades at $88.11, up 1.23% on the day, with a mixed technical outlook showing a bullish overall signal but bearish oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q3 2026 results pending. Revenue and net income are projected to grow in 2026, supported by a 15.43% net income margin. Analyst sentiment is cautious with a 32.35% buy rating, but the consensus price target of $96.38 suggests upside potential. Recent news highlights data center demand and dividend stability, though near-term cash flow pressure from high capital expenditures is a concern.
The outlook for SO is balanced, with long-term growth driven by utility demand and data center contracts, but near-term risks include capital expenditure pressures and potential data breach impacts. The stock offers a stable dividend and is positioned for gradual appreciation if earnings continue to outperform, yet investors should monitor cash flow trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Southern Company
Southern Company is a U.S. energy company with electric and gas utility businesses. Its power generation portfolio includes natural gas, nuclear, renewable, and other energy sources.
Read more on SO →
